Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 1
1955 1
1959 2
1960 2
1961 1
1962 1
1963 1
1971 1
1974 1
1976 1
1977 1
1981 1
1982 1
1983 1
1984 1
1985 4
1986 1
1987 1
1989 2
1990 1
1991 1
1992 2
1994 1
1995 2
1998 3
1999 2
2000 1
2001 4
2002 4
2003 8
2004 6
2005 13
2006 11
2007 21
2008 38
2009 39
2010 38
2011 25
2012 31
2013 40
2014 28
2015 29
2016 40
2017 40
2018 40
2019 34
2020 40
2021 47
2022 54
2023 48
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

642 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. Cantini L, et al. Among authors: vidal l. Cancer Treat Rev. 2024 Feb;123:102669. doi: 10.1016/j.ctrv.2023.102669. Epub 2023 Dec 10. Cancer Treat Rev. 2024. PMID: 38141462 Review.
Refractory fibromyalgia.
Vidal LF, Messina O, Rodríguez T, Vidal M, Pineda C, Morales R, Collado A. Vidal LF, et al. Clin Rheumatol. 2021 Sep;40(9):3853-3858. doi: 10.1007/s10067-021-05818-0. Epub 2021 Jun 24. Clin Rheumatol. 2021. PMID: 34169373 Review.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Frenel JS, et al. Among authors: vidal l. Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27. Ann Oncol. 2022. PMID: 35772665 Free article. Clinical Trial.
Beyond the Spinal Canal.
Raghavan P, Record J, Vidal L. Raghavan P, et al. Among authors: vidal l. Radiol Clin North Am. 2019 Mar;57(2):453-467. doi: 10.1016/j.rcl.2018.09.009. Epub 2018 Nov 28. Radiol Clin North Am. 2019. PMID: 30709480 Review.
Management of glucocorticoid-induced osteoporosis.
Messina OD, Vidal LF, Wilman MV, Bultink IEM, Raterman HG, Lems W. Messina OD, et al. Among authors: vidal lf. Aging Clin Exp Res. 2021 Apr;33(4):793-804. doi: 10.1007/s40520-021-01823-0. Epub 2021 Mar 22. Aging Clin Exp Res. 2021. PMID: 33751462 Review.
Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update.
Messina OD, Vidal M, Adami G, Vidal LF, Clark P, Torres JAM, Lems W, Zerbini C, Arguissain C, Reginster JY, Lane NE. Messina OD, et al. Among authors: vidal lf. Aging Clin Exp Res. 2023 Jul;35(7):1405-1416. doi: 10.1007/s40520-023-02432-9. Epub 2023 May 24. Aging Clin Exp Res. 2023. PMID: 37222927 Free article. Review.
642 results